Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00761644 · ClinicalTrials.gov registry record · Phase 1
Doxil, Bevacizumab and Temsirolimus Trial
A Phase 1 study of Advanced Cancer, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 200
- Enrollment target
- 1
- Study location
NCT00761644 is a Phase 1 study of Advanced Cancer that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 200 participants, below the 245-participant average among 122 other Advanced Cancer trials with a reported enrollment target (18% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00761644, a Phase 1 study of Advanced Cancer, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical research study is to learn the highest safe doses of the combination of Doxil (liposomal doxorubicin), Avastin (bevacizumab), and Torisel (Temsirolimus) that can be given to patients with advanced cancer that has spread or is unable to be surgically removed. The safety and effectiveness of this combination of drugs will also be studied.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Doxil
- DRUG Temsirolimus
Study Locations (1)
Texas
- University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2008-08-21 |
| Est. Completion | 2019-03-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00761644
The ClinicalTrials.gov registry entry for NCT00761644 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 245-participant average among 122 other Advanced Cancer trials with a reported enrollment target (18% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Cancer appearing as the primary indexed condition, and to 3 interventions - of which Bevacizumab is the first listed.
NCT00761644 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00761644 about?
NCT00761644 is a clinical study titled "Doxil, Bevacizumab and Temsirolimus Trial". The goal of this clinical research study is to learn the highest safe doses of the combination of Doxil (liposomal doxorubicin), Avastin (bevacizumab), and Torisel (Temsirolimus) that can be given to patients with advanced cancer that has spread or is unable to be surgically removed. The safety and ...
What is the current status of trial NCT00761644?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 200 participants. The study started on 2008-08-21. Estimated completion is 2019-03-28.
What conditions does trial NCT00761644 study?
This clinical trial studies the following conditions: Advanced Cancer.
What interventions are being tested in trial NCT00761644?
The interventions under investigation include: Bevacizumab (DRUG), Doxil (DRUG), Temsirolimus (DRUG).
Who is sponsoring clinical trial NCT00761644?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00761644 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss
RECRUITING · Phase 1
-
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study in Patients With Advanced Cancers
RECRUITING · Phase 1
-
A Study of MGC026 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.